Kallyope Inc.
Clinical trials sponsored by Kallyope Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New migraine pill aims to stop pain in 2 hours – major trial underway Results expected Feb 2027 (estimated)
- Can a pill stop a migraine in two hours? Results expected Sep 2027 (estimated)
-
Migraine drug tested for Long-Term safety in 1,000-Person trial
Symptom relief Recruiting nowThis phase 3 study evaluates the long-term safety of elismetrep (K-304), an oral medication taken as needed for migraine attacks. About 1,000 adults who previously took elismetrep in an earlier trial will continue using it intermittently. Researchers will track side effects over …
Phase 3 • Sponsor: Kallyope Inc. • Aim: Symptom relief
Last updated Aug 29, 2026 00:00 UTC
-
New migraine pill aims to stop pain in 2 hours – major trial underway
Symptom relief Recruiting nowThis study tests a new drug, elismetrep, to see if it can quickly stop migraine pain and bothersome symptoms like nausea or light sensitivity. About 1800 adults with frequent migraines will receive either the drug or a placebo. The main goal is to measure how many people are pain…
Phase 3 • Sponsor: Kallyope Inc. • Aim: Symptom relief
Last updated Aug 22, 2026 00:00 UTC